Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Timothy Madden | Researchclopedia

Back to researchers

Timothy Madden

Fujifilm (United States)ORCID

179

Works

6,175

Citations

41

h-index

71

i10-index

Research Topics

Cancer therapeutics and mechanisms Cancer Treatment and Pharmacology Acute Myeloid Leukemia Research

Affiliations

Ontario Institute for Cancer Research2012–2012

St. Jude Children's Research Hospital1992–1994

The University of Texas MD Anderson Cancer Center1994–2016

Reata Pharmaceuticals (United States)2006–2007

Thomas Jefferson University2009–2009

Top Works

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

Christos N. Papandreou,Danai Daliani,et al.

2004437 citations

Hematopoietic Stem Cell Transplantation

Cancer, Hypoxia, and Metabolism

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

Marcos de Lima,Daniel R. Couriel,et al.

2004422 citations

A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo

Arifumi Iwamaru,Sławomir Szymański,et al.

2006369 citations

A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients

S. Farzana Hussain,Ling-Yuan Kong,et al.

2007311 citations

Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors

Roy S. Herbst,Kenneth R. Hess,et al.

2002277 citations

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

Andrzej P. Kudelka,Damrong Tresukosol,et al.

1996252 citations

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia

Börje S. Andersson,Peter F. Thall,et al.

2002227 citations

Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin

Roy S. Herbst,Nizar A. Mullani,et al.

2002180 citations

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Deborah J. Kuhn,Zuzana Berkova,et al.

2012172 citations